In summary, as a prospective inhibitor of CDK7, THZ2 can alleviate the inflammatory symptoms, both in DSS-induced acute colitis and AOM/DSS-induced colorectal cancer mouse models, inhibiting colitis and tumor cell proliferation. Here, CDK7 is linked to neoplasm.